Premium
Pharmacokinetics of benzydamine after intravenous, oral, and topical doses to human subjects
Author(s) -
Baldock G. A.,
Brodie R. R.,
Chasseaud L. F.,
Taylor T.,
Walmsley L. M.,
Catanese B.
Publication year - 1991
Publication title -
biopharmaceutics and drug disposition
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.419
H-Index - 58
eISSN - 1099-081X
pISSN - 0142-2782
DOI - 10.1002/bdd.2510120702
Subject(s) - pharmacokinetics , medicine , drug , oral administration , pharmacology , volume of distribution , absorption (acoustics) , limiting , distribution (mathematics) , mechanical engineering , mathematical analysis , physics , mathematics , acoustics , engineering
The pharmacokinetics of the anti‐inflammatory drug benzydamine were determined after intravenous infusion of 5 mg to six healthy male subjects. Benzydamine was characterized as a drug of relatively low systemic clearance (ca. 160 ml min −1 ) but high volume of distribution (ca. 1101); the apparent terminal half‐life in plasma was ca. 8h. Benzydamine was well absorbed after oral administration, as indicated by a mean systemic availability of 87 per cent. However, absorption of the drug was low (<10 per cent of the dose) after its use by male subjects as a mouthwash, or after its application to female subjects as dermal cream and vaginal douche preparations. The data suggest that benzydamine is generally not well absorbed through the skin and non‐specialized mucosae, thereby limiting unrequired systemic exposure to this drug when it is used by these routes.